# INDIGO (NCT04164901)

> Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04164901
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Institut de Recherches Internationales Servier
- Conditions: Grade 2 Glioma; Residual Glioma; Recurrent Glioma
- Interventions: Vorasidenib; Matching Placebo
- Enrollment: 331
- Primary outcome: Progression-Free Survival (PFS)

## Indexed commentary on INDIGO so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 7

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=indigo-nct04164901